DMP 696 is a selective antagonist of corticotropin-releasing hormone receptor 1. It is used for the treatment of anxiety and depression.

DMP696 treatment decreases levels of LA and BLA pCREB to homecage pCREB levels across all time intervals. DMP696 (3 mg/kg, p.o.) attenuates consolidation of remote fear memories in mice, without affecting expression and retention. Rats treated with DMP696 (1, 3, 10, 30 mg/kg) show minimal freezing during a 2-minute preshock interval. WT mice treated with DMP696 for 1 week starting 24 hours after foot shock display reduced synaptosomal GluR1 levels compared to shocked vehicle-treated controls [1]. DMP696 significantly reduces CREB phosphorylation in LA and BLA but not in CeA. In the CeA, both vehicle- and DMP696-treated rats exhibit higher pCREB expression post-conditioning compared to homecage pCREB levels. Rats in the 30 ng DMP696 group exhibit significantly less freezing compared to vehicle-treated animals [2].